Global Analog to Digital Converters Market Size (2026-2032) Technology Innovation, Opportunities by Region, Recent Developments and Competitive Analysis by Key Players

The Animal Model Market size was valued at USD 22.21 Billion in 2025 and the total Animal Model revenue is expected to grow at a CAGR of 6.5% from 2025 to 2034, reaching nearly USD 39.16 Billion.

Animal Model Market Overview:

The Global Animal Model Market is experiencing steady growth, driven by increasing investments in biomedical research, drug discovery, and preclinical testing across the pharmaceutical, biotechnology, and academic sectors. Animal models play a critical role in understanding disease mechanisms, evaluating drug safety and efficacy, and supporting translational research before human clinical trials. Commonly used animal models include mice, rats, zebrafish, rabbits, guinea pigs, and non-human primates, with genetically engineered and humanized models gaining significant importance in oncology, immunology, neuroscience, cardiovascular diseases, and infectious disease research. The market is benefiting from rising pharmaceutical research and development (R&D) expenditures, increasing prevalence of chronic and rare diseases, growing adoption of precision medicine, and advancements in gene-editing technologies such as CRISPR-Cas9. Furthermore, expanding collaborations between research institutions, contract research organizations (CROs), and biotechnology companies are accelerating innovation and supporting the demand for advanced animal models.

The market is expected to witness significant expansion during the forecast period, supported by continuous advancements in genetically modified animal models, personalized medicine research, and regenerative medicine. The integration of CRISPR-based genome editing, transgenic technologies, humanized mouse models, and AI-assisted preclinical research is improving the accuracy, reproducibility, and efficiency of biomedical studies. Increasing investments in vaccine development, cell and gene therapy, immunotherapy, and neurological disorder research are creating substantial growth opportunities for animal model providers. In addition, the expansion of contract research services, rising government funding for life science research, and growing demand for customized disease-specific animal models are further strengthening market growth. Although stringent ethical regulations, high maintenance costs, and increasing adoption of alternative in vitro and organ-on-chip technologies present challenges, ongoing technological advancements and the continued need for reliable preclinical research tools are expected to sustain long-term growth in the Global Animal Model Market.

To know about the Research Methodology :- Request Free Sample Report

Animal Model Market Dynamics:

Rising investments in pharmaceutical research and drug discovery are accelerating market growth

Increasing research and development spending by pharmaceutical and biotechnology companies is significantly driving the Animal Model Market. Animal models remain indispensable for preclinical testing, drug efficacy evaluation, toxicology studies, and disease mechanism research before human clinical trials. Growing investments in oncology, immunology, neuroscience, infectious diseases, and rare disease therapeutics are increasing the demand for genetically engineered and disease-specific animal models. In addition, expanding government funding, academic research initiatives, and collaborations between research institutions and contract research organizations (CROs) continue to strengthen market growth.

Advancements in genetic engineering technologies are creating new research opportunities

Continuous innovations in CRISPR-Cas9, transgenic technologies, and humanized animal models are transforming biomedical research by enabling the development of highly accurate disease models. These advanced models improve the understanding of complex genetic disorders and enhance the success rate of drug development programs. Increasing adoption of precision medicine, gene therapy, regenerative medicine, and personalized therapeutics is encouraging manufacturers and research organizations to develop customized animal models with improved translational relevance, creating significant growth opportunities across the global market.

Ethical concerns and stringent regulatory requirements continue to challenge market expansion

Despite strong demand, ethical issues associated with animal testing and increasingly stringent regulations governing laboratory animal welfare remain major challenges for the market. Regulatory authorities and research organizations are promoting the principles of Replacement, Reduction, and Refinement (3Rs), encouraging researchers to minimize animal usage wherever possible. Compliance with animal welfare regulations, licensing requirements, and institutional ethical review processes increases operational complexity and research costs, particularly for pharmaceutical companies and research laboratories conducting large-scale preclinical studies.

Growing adoption of alternative testing technologies is reshaping preclinical research

The rapid development of organ-on-chip platforms, three-dimensional (3D) cell cultures, organoids, computational biology, and artificial intelligence-based predictive models is gradually transforming preclinical research. These technologies offer faster, cost-effective, and ethically acceptable alternatives for early-stage drug screening and toxicity assessment. However, animal models continue to remain essential for evaluating complex biological interactions, systemic responses, and long-term safety profiles, ensuring their continued importance in biomedical research while driving the adoption of more integrated and complementary research approaches.

Animal Model Market Trends:

Growing adoption of CRISPR-Cas9 technology for genetically engineered animal models - CRISPR-based genome editing is enabling researchers to develop highly precise disease-specific animal models for oncology, neurological disorders, cardiovascular diseases, and rare genetic conditions. The technology is significantly reducing model development time while improving research accuracy and reproducibility.

Increasing use of humanized animal models in precision medicine research - Humanized mouse models are witnessing growing adoption across immunology, oncology, infectious disease, and cell & gene therapy research due to their ability to closely mimic human biological responses. Pharmaceutical companies are increasingly utilizing these models to accelerate drug development and improve clinical translation.

Expansion of contract research organizations in preclinical testing - Pharmaceutical and biotechnology companies are increasingly outsourcing preclinical research activities to specialized CROs to reduce costs, improve operational efficiency, and accelerate drug development timelines. This trend is driving demand for high-quality animal models and customized research services.

Growing investment in rare disease and personalized therapy research - The increasing focus on precision medicine, gene therapy, and regenerative medicine is encouraging research institutions to develop customized transgenic animal models for specific genetic disorders. These models are improving therapeutic discovery and supporting the development of targeted treatment approaches.

Integration of artificial intelligence and digital pathology in preclinical research - Artificial intelligence, machine learning, automated imaging, and digital pathology are increasingly being integrated into animal research workflows to enhance data analysis, improve study accuracy, and optimize experimental outcomes. These technologies are enabling faster and more efficient preclinical research processes.

Rising emphasis on ethical research and alternative testing approaches - Research organizations are increasingly adopting advanced monitoring systems, improved animal welfare practices, and complementary in vitro technologies to comply with evolving ethical standards while maintaining the scientific value of animal-based research. Continuous improvements in laboratory animal care and refinement techniques are becoming key priorities across the industry.

Animal Model Market Segment Analysis:

Based on Species, the Animal Model Market is divided into Mice and Rats, Zebrafish, Rabbits, Monkeys, Dogs, Pigs, Cats, and Other Species. Mice and Rats dominated the market in 2025, owing to their widespread use in biomedical research, drug discovery, toxicology testing, and disease modeling. Their well-characterized genomes, short reproductive cycles, low maintenance costs, and availability of numerous genetically engineered and transgenic strains make them the preferred animal models for pharmaceutical companies, biotechnology firms, and academic institutions. Advances in CRISPR gene-editing technologies and the increasing adoption of humanized mouse models have further strengthened the dominance of this segment, particularly in oncology, immunology, neuroscience, and infectious disease research.

Zebrafish are expected to witness the fastest growth during the forecast period, driven by their increasing use in developmental biology, genetic studies, regenerative medicine, and high-throughput drug screening. Their transparent embryos, rapid development, and genetic similarity to humans make them highly valuable for early-stage biomedical research. Rabbits continue to play an important role in antibody production, ophthalmology, and vaccine development, while Monkeys remain indispensable for neuroscience, infectious disease, and vaccine research due to their close physiological resemblance to humans. Dogs, Pigs, and Cats continue to support specialized research in cardiovascular diseases, metabolic disorders, transplantation, and surgical training, whereas the Other Species segment, including guinea pigs, hamsters, and non-traditional laboratory animals, contributes to niche research applications across toxicology, immunology, and infectious disease studies.

Based on End User, the Animal Model Market is divided into Academic & Research Institutions, Pharmaceutical Companies, Biotechnology Companies, and Contract Research Organizations (CROs). Pharmaceutical Companies dominated the market in 2025, supported by substantial investments in drug discovery, preclinical safety assessment, and regulatory toxicology studies. The growing pipeline of novel therapeutics, biologics, vaccines, and cell and gene therapies has significantly increased the demand for high-quality animal models across multiple therapeutic areas. Pharmaceutical companies continue to invest in genetically engineered animal models and advanced preclinical platforms to improve drug development efficiency and increase clinical success rates.

Contract Research Organizations (CROs) are expected to register the fastest growth during the forecast period, as pharmaceutical and biotechnology companies increasingly outsource preclinical research to reduce operational costs, access specialized expertise, and accelerate product development timelines. Academic & Research Institutions continue to account for a significant share of the market due to increasing government funding, university-led biomedical research, and disease mechanism studies. Meanwhile, Biotechnology Companies are expanding their use of advanced animal models to support innovation in precision medicine, gene editing, immunotherapy, regenerative medicine, and rare disease research, further contributing to the sustained growth of the Animal Model Market.

Animal Model Market Regional Insights:

North America dominated the Animal Model Market in 2025 and is expected to maintain its leading position throughout the forecast period, driven by substantial investments in pharmaceutical and biotechnology research, a well-established life sciences industry, and the presence of leading contract research organizations (CROs) and academic institutions. The United States accounts for the largest regional market share owing to high research and development (R&D) expenditure, increasing drug discovery activities, and extensive use of genetically engineered and humanized animal models in oncology, neuroscience, immunology, and infectious disease research. Strong government funding, advanced biomedical infrastructure, and the presence of major pharmaceutical companies further support regional market growth. Additionally, the rapid adoption of CRISPR-based genome editing technologies and personalized medicine research continues to strengthen North America's leadership in the global market.

Asia Pacific is expected to register the fastest growth during the forecast period, supported by expanding pharmaceutical manufacturing, increasing biotechnology investments, and rising government funding for biomedical research across China, Japan, South Korea, and India. China is rapidly strengthening its preclinical research capabilities through investments in genetically engineered animal model production and contract research services, while Japan remains a key center for regenerative medicine and translational research. Europe continues to witness steady growth owing to its strong pharmaceutical industry, advanced academic research infrastructure, and stringent regulatory standards supporting high-quality preclinical studies. Latin America is gradually emerging as a promising market due to increasing investments in clinical research, expanding healthcare infrastructure, and growing collaborations with international pharmaceutical companies. Meanwhile, the Middle East & Africa is expected to experience moderate growth, driven by improving research capabilities, expanding biotechnology initiatives, and increasing government support for life sciences and biomedical innovation.

Animal Model Market Recent Industry Developments:

Animal Model Market Competitive Landscape:

The Animal Model Market is characterized by the presence of global laboratory animal suppliers, contract research organizations (CROs), and biotechnology companies that compete through genetic engineering capabilities, breeding expertise, research collaborations, and geographically diversified production facilities. Market participants are investing in advanced CRISPR-Cas9 gene-editing technologies, humanized animal models, transgenic breeding programs, and pathogen-free animal production to meet the growing demand from pharmaceutical companies, biotechnology firms, and academic research institutions. Strategic initiatives such as acquisitions, partnerships with research organizations, facility expansions, and investments in breeding infrastructure are enabling companies to strengthen their market positions while supporting the increasing volume of preclinical studies worldwide.

Leading companies including The Jackson Laboratory, Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Envigo (Inotiv), Janvier Labs, genOway S.A., Harbour BioMed, Trans Genic Inc., Cyagen Biosciences, and Crown Bioscience are continuously expanding their genetically engineered animal model portfolios and preclinical research services. Companies are also focusing on customized disease-specific models, humanized mice, and integrated drug discovery solutions to support oncology, immunology, neuroscience, and gene therapy research. As demand for precision medicine and biologics continues to increase, technological innovation, global breeding capacity expansion, and strategic collaborations are expected to remain the primary competitive strategies across the Animal Model Market.

Animal Model Market Scope: Inquire Before Buying

Animal Model Market, by Region:

North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan, and the Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria, and the Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Key Players in the Animal Model Market

North America

1. Charles River Laboratories International, Inc.
2. The Jackson Laboratory
3. Inotiv, Inc.
4. Taconic Biosciences, Inc.
5. Crown Bioscience, Inc.
6. Transposagen Biopharmaceuticals, Inc.
7. Hera Biolabs
8. Cyagen Biosciences Inc.

Europe

9. genOway S.A.
10. Eurofins Scientific SE
11. Janvier Labs
12. Ingenious Targeting Laboratory
13. Harlan Laboratories B.V.

Asia Pacific

14. Trans Genic Inc.
15. Japan SLC, Inc.
16. CLEA Japan, Inc.
17. Ozgene Pty Ltd.
18. Shanghai Model Organisms Center, Inc.
19. GemPharmatech Co., Ltd.
20. Beijing Biocytogen Co., Ltd.
21. Harbour BioMed

Rest of the World

22. Animal Resources Centre
23. Australian BioResources Pty Ltd.
24. CERJ Janvier

Others

Frequently Asked Questions:

1. What are the growth drivers for the Animal Model Market?
Ans. The growing importance of genetic research and engineering contributes to the demand for genetically modified animal models. These models allow researchers to study specific genes and their functions, facilitating advancements in genetics and molecular biology.

2. What is the major Opportunity for the Animal Model Market growth?
Ans. One major opportunity for the growth of the animal model market lies in the advancements and opportunities associated with genomic editing technologies.

3. Which country is expected to lead the global Animal Model Market during the forecast period?
Ans. North America is expected to lead the Animal Model Market during the forecast period.

4. What is the projected market size and growth rate of the Animal Model Market?
Ans. The Animal Model Market size was valued at USD 22.21 Billion in 2025 and the total Animal Model revenue is expected to grow at a CAGR of 6.5% from 2025 to 2034, reaching nearly USD 39.16 Billion.

5. What segments are covered in the Animal Model Market report?
Ans. The segments covered in the Animal Model Market report are by species, Application, end user, and Region.